Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape
Angelo Antonini, Robert E Gross, Maria De Leon, Kevin Kwok, Tom Foltynie, Günter Höglinger, Thomas Gasser, Jean-Christophe Corvol, David J. Pedrosa, Jens Volkmann, Claire Henchcliffe · 2026
Read Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape by Angelo Antonini, Robert E Gross, Maria De Leon, Kevin Kwok, Tom Foltynie, Günter Höglinger, Thomas Gasser, Jean-Christophe Corvol, David J. Pedrosa, Jens Volkmann, Claire Henchcliffe (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13578137.txt.
Description
Angelo Antonini and co-authors wrote a 2026 review that rethinks what disease modification means in Parkinson disease. More and more candidate treatments that might slow the disease are in trials. Current definitions of that goal, though, carry built in limits.
The authors call for one clear definition that fits both the common form and the genetic forms of the disease. It must reach past motor signs to milestones such as thinking loss and autonomic faults, across all stages. The review weighs past definitions and argues for a wider lens that folds in the views of patients, clinicians, and researchers. The goal is a shared yardstick for judging the new drugs.
Catalog record
| CREATOR | Angelo Antonini, Robert E Gross, Maria De Leon, Kevin Kwok, Tom Foltynie, Günter Höglinger, Thomas Gasser, Jean-Christophe Corvol, David J. Pedrosa, Jens Volkmann, Claire Henchcliffe |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |